respiratori
viral
infect
global
health
concern
caus
dozen
differ
type
virus
respiratori
diseas
result
viral
infect
repres
one
main
caus
death
develop
thorough
understand
respiratori
virus
epidemiolog
well
medic
impact
commun
affect
delin
path
toward
eventu
treatment
futur
abat
ill
symptom
mani
respiratori
virus
similar
virus
characterist
uniqu
categor
virus
group
base
similar
natur
nucleic
acid
genom
envelop
presenc
overal
size
even
capsid
review
focus
follow
famili
rna
virus
orthomyxovirida
paramyxovirida
pneumovirida
picornavirida
coronavirida
orthomyxovirida
compris
neg
sens
singlestrand
ss
rna
virus
segment
envelop
includ
influenza
virus
see
tabl
paramyxovirida
pneumovirida
also
ssrna
virus
nonseg
envelop
includ
parainfluenza
viru
piv
human
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
picornavirida
famili
contain
posit
ssrna
virus
nonenvelop
key
member
includ
rhinovirus
enterovirus
lastli
coronavirida
ssrna
envelop
virus
includ
chiefli
human
coronaviru
hcov
sever
acut
respiratori
syndrom
sar
associ
middl
eastern
respiratori
syndrom
mer
young
children
elderli
patient
compromis
cardiac
pulmonari
immun
system
greatest
risk
seriou
diseas
associ
rna
viru
respiratori
infect
studi
acut
respiratori
viral
infect
critic
ill
children
admit
pediatr
intens
care
unit
caus
either
picornaviru
rsv
piv
hmpv
see
figur
dna
virus
adenoviru
sourc
respiratori
infect
discuss
addit
wide
variat
viral
characterist
respiratori
rna
virus
also
remark
epidemiolog
varieti
differ
outbreak
calendar
season
other
yearround
patient
profil
whether
infant
geriatr
otherwis
healthi
adult
morbid
andor
mortal
associ
infect
influenza
viru
ssrna
viru
member
orthomyxovirida
four
influenza
genera
within
famili
call
b
c
influenza
b
contain
hemagglutinin
neuraminidas
envelop
glycoprotein
influenza
c
singl
surfac
glycoprotein
call
hemagglutininesteras
fusion
antigen
variat
glycoprotein
result
limit
vaccin
protect
influenza
flu
present
symptom
headach
cough
fever
sore
throat
malais
gener
flu
last
day
week
sever
infect
determin
host
highest
incid
influenza
infect
occur
younger
patient
year
old
shorter
infect
typic
risk
longer
sever
ill
complic
associ
infect
pediatr
year
old
geriatr
popul
year
old
pregnant
women
immunocompromis
estim
million
case
flu
occur
annual
around
globe
quarter
half
million
death
result
recent
piv
hmpv
rsv
categor
paramyxovirida
famili
due
phylogenet
proxim
order
mononegaviral
nonseg
negativestrand
rna
virus
recent
rsv
hmpv
assign
member
newli
form
pneumovirida
influenza
outbreak
preval
winter
virus
piv
persist
yearround
human
piv
four
type
known
histor
induc
respiratori
complic
mainli
children
immunocompromis
howev
recent
identifi
concern
adult
popul
symptom
piv
includ
upper
lower
respiratori
tract
infect
middl
ear
inflamm
bronchiti
pneumonia
croup
last
result
hospit
pediatr
patient
infect
onethird
nearli
million
annual
case
lower
respiratori
tract
infect
children
least
partial
due
presenc
rsv
piv
infect
among
common
reason
hospit
young
two
strain
rsv
b
distinguish
genet
variat
g
surfac
dissimilar
piv
rsv
occur
mostli
winter
month
target
pediatr
popul
symptom
includ
runni
nose
nasal
inflamm
cough
sore
throat
lowgrad
fever
wheez
bronchiol
current
estim
develop
industri
countri
suggest
mani
million
case
rsv
worldwid
pediatr
popul
less
year
old
requir
hospit
hospit
case
result
mortal
amount
death
young
children
hmpv
like
rsv
influenza
tend
greatest
preval
winter
studi
shown
age
year
nearli
children
infect
clinic
manifest
infect
viru
upper
lower
respiratori
tract
infect
bronchiol
middl
ear
inflamm
fever
chill
pneumon
note
hmpv
tend
occur
popul
season
inconsist
studi
done
italian
popul
shortli
discoveri
show
rang
infect
depend
year
pattern
season
irregular
like
note
respiratori
virus
particularli
rsv
present
six
hcov
recogn
wellknown
sar
mer
cov
character
base
genera
alpha
beta
gamma
delta
alpha
beta
cov
compris
six
virus
mention
infect
human
cov
pathogen
associ
common
cold
caus
pneumonia
infect
show
similar
clinic
featur
patient
clinician
also
report
bronchiol
croup
pneumonia
infect
first
cov
recogn
pandem
threat
sarscov
sar
discov
perplex
epidem
pneumonia
among
hospit
worker
end
global
epidem
sar
dissemin
countri
infect
individu
kill
roughli
roughli
decad
later
similar
pattern
occur
mer
began
jordan
outbreak
respiratori
ill
among
hospit
worker
one
die
infect
later
year
man
pneumonia
multipl
organ
failur
saudi
arabia
found
mer
adult
target
popul
sar
mer
median
age
rang
year
mer
occur
predominantli
men
wherea
sar
clinic
featur
sar
mer
rang
mild
sever
respiratori
ill
fever
chill
cough
short
breath
vomit
diarrhea
latter
display
lethal
pneumonia
renal
even
wors
sar
mortal
retrospect
analysi
shown
confirm
case
mer
nucleosid
analog
repres
one
domin
class
antivir
agent
due
widespread
use
common
chronic
infect
caus
human
immunodefici
viru
hiv
hepat
b
viru
herpesvirus
past
year
multipl
nucleosid
nucleotid
analog
develop
directact
agent
rna
viru
infect
hepat
c
viru
hcv
yet
success
appli
acut
infect
caus
respiratori
virus
hand
nonnucleosid
drug
develop
treatment
prevent
virus
drug
includ
fda
approv
oseltamivir
zanamivir
peramivir
influenza
viru
infect
palivizumab
rsv
prevent
well
two
discontinu
clinic
candid
target
rhinoviru
pleconaril
rupintrivir
molecul
possess
limit
prevent
widespread
use
short
therapeut
window
risk
resist
select
neuraminidas
inhibitor
partial
protect
associ
prophylact
use
palivizumab
provid
impetu
approv
new
drug
broader
therapeut
use
recogn
advantag
directact
agent
nucleosid
class
antivir
agent
propens
cover
broadspectrum
viru
strain
sometim
speci
high
barrier
antivir
resist
properti
best
explain
mechan
action
common
antivir
nucleosid
target
viral
metabol
host
kinas
triphosph
form
antivir
nucleotid
compet
natur
nucleosid
triphosph
ntp
bind
activ
site
viral
polymeras
alter
dna
rna
synthesi
nucleotid
bind
site
protein
usual
well
conserv
among
viru
famili
chang
neighbor
amino
acid
often
come
cost
enzym
viru
function
structur
featur
rna
polymeras
respiratori
virus
target
antivir
nucleosid
describ
follow
paragraph
influenza
viru
ssrna
viru
member
orthomyxovirida
viral
genom
eight
segment
influenza
b
seven
segment
influenza
c
influenza
encod
protein
nonstructur
protein
nonstructur
protein
matrix
protein
ion
channel
protein
polymeras
acid
pa
protein
polymeras
basic
protein
polymeras
basic
protein
polymeras
basic
protein
nucleoprotein
np
hemagglutinin
ha
neuraminidas
na
virus
express
protein
four
speci
influenza
adopt
similar
arrang
viral
genom
segment
form
viral
ribonucleoprotein
complex
associ
one
heterotrimer
polymeras
influenza
polymeras
compos
three
subunit
yield
kda
heterotrimer
complex
longest
viral
rna
segment
encod
pa
protein
assembl
form
influenza
polymeras
complex
see
figur
three
subunit
interact
noncoval
exert
polymeras
activ
polymeras
transcrib
viral
rna
messeng
rna
mrna
replic
use
complementari
rna
process
transcript
includ
cap
snatch
shortcap
cellular
rna
bound
subunit
cleav
pa
endonucleas
domain
util
prime
mrna
synthesi
subunit
ntermin
domain
residu
ctermin
domain
residu
includ
lid
domain
interact
ctermin
extens
thumb
includ
sever
notabl
structur
featur
subdomain
ctermin
nuclear
local
signal
linker
mid
domain
cap
bind
base
structur
biolog
domain
key
exterior
posit
charg
residu
posit
within
flexibl
loop
partial
wrap
around
alpha
helix
form
known
importantli
residu
middl
set
highli
conserv
basic
residu
form
net
posit
charg
signatur
structur
element
conserv
p
fp
aaapp
motif
ntermin
side
residu
part
alpha
helix
previous
mutat
residu
significantli
decreas
abil
viru
replic
presum
caus
slight
kink
alpha
helix
alter
polymeras
function
exact
role
domain
remain
unclear
recent
evid
suggest
necessari
vitro
bind
transcript
viral
rna
proven
true
cellbas
domain
center
polymeras
complex
within
center
classic
righthand
shape
signatur
finger
palm
thumb
subdomain
see
figur
subdomain
describ
conserv
rnadepend
rna
polymeras
rdrp
motif
preaf
preaf
motif
describ
fingertip
small
loop
spread
thumb
domain
tip
loop
stabil
alpha
helix
within
pa
domain
residu
within
preaf
may
guid
bind
ntp
incom
templat
addit
subdomain
ntermin
ctermin
extens
interact
pa
domain
finger
palm
cover
linker
connect
two
subdomain
pa
possess
loop
within
motif
e
residu
thumb
subdomain
influenza
de
novo
initi
shown
relat
polymeras
prime
loop
may
serv
platform
initi
ntp
end
templat
ensur
doublestrand
rna
biochem
investig
shown
prolin
found
within
loop
tip
motif
necessari
vitro
cellbas
rna
synthesi
loop
may
also
necessari
replic
mode
termin
de
novo
initi
unnecessari
intern
initi
pa
endonucleas
domain
pa
subunit
name
littl
homolog
protein
exact
enzymat
function
discov
recent
subunit
express
insect
cell
reveal
ntermin
third
panter
ctermin
twothird
pacter
subdomain
molecular
weight
kda
respect
two
subdomain
connect
flexibl
linker
endonucleas
activ
origin
thought
occur
domain
structur
panter
solv
two
group
reveal
catalyt
residu
endonucleas
activ
resid
pa
domain
subunit
origin
pa
endonucleas
domain
contain
signatur
p
dxn
de
xk
motif
conserv
among
influenza
virus
coordin
dival
cation
magnesium
although
exact
quantiti
ident
ion
present
nativ
influenza
enzym
unclear
endonucleas
activ
strongli
activ
metal
ion
bind
hydrolysi
ssdna
ssrna
substrat
human
metapneumoviru
human
rsv
nonseg
neg
strand
rna
virus
pneumovirida
famili
order
mononegaviral
polymeras
class
virus
multifacet
multipl
enzymat
function
contain
within
singl
protein
exist
part
ribonucleoprotein
complex
replicas
compos
l
n
p
protein
complex
rna
includ
rna
synthesi
activ
carri
rdrp
domain
also
includ
cap
methyl
function
rdrp
carri
transcript
replic
genom
respons
cisact
element
within
genom
rsv
approxim
kilobas
long
transcrib
cap
polyadenyl
hmpv
genom
kilobas
long
current
understand
hmpv
transcript
base
knowledg
gain
extens
character
rsv
transcript
focu
begin
end
viral
gene
lie
conserv
region
cr
nucleotid
nucleotid
respect
term
gene
start
gs
gene
end
ge
signal
intergen
nontranscrib
region
gene
side
genom
prior
first
gene
leader
le
extragen
region
end
trailer
tr
extragen
region
length
extragen
region
vari
base
viru
rsv
le
region
nucleotid
long
transcrib
rna
polymeras
initi
third
nucleotid
transcrib
short
uncap
transcript
rna
releas
polymeras
remain
affix
templat
proce
along
encount
gs
signal
first
gene
subsequ
begin
rna
synthesi
mrna
modifi
methyl
cap
ge
signal
reach
polyadenyl
tail
ad
mrna
releas
polymeras
scan
next
gs
region
genom
replic
start
leader
promot
process
manner
yield
posit
sens
antigenom
rna
end
antigenom
contain
trailer
leader
complement
trailer
complement
ultim
direct
genom
rna
synthesi
core
rsv
polymeras
consist
kda
larg
l
protein
approxim
amino
acid
kda
phosphoprotein
p
synthes
rna
product
upon
addit
rna
p
protein
thought
act
chaperon
aid
stabil
express
polymeras
rna
synthesi
p
protein
anchor
l
protein
n
protein
also
bind
transcript
antitermin
matrix
protein
serv
elong
factor
necessari
polymeras
fulli
process
produc
long
mrna
structur
avail
l
protein
paramyxovirus
pneumovirus
larg
due
size
solubl
complex
yield
enough
highli
pure
protein
howev
cryoelectron
microscop
em
structur
lp
complex
highli
similar
viru
vesicular
stomat
viru
vsv
recent
vsv
nonseg
neg
strand
viru
rhabdovirida
famili
given
high
sequenc
conserv
l
protein
structur
vsv
l
provid
import
structur
insight
l
protein
rsv
vsv
relat
neg
sens
rna
polymeras
divid
six
first
three
region
criiii
vsv
gener
doughnutlik
structur
neg
stain
em
cryoem
remain
cr
appear
globular
appendag
doughnut
doughnut
structur
adopt
classic
righthand
configur
cryoem
reconstruct
compos
finger
palm
thumb
domain
like
polymeras
see
figur
criv
crv
contain
conserv
residu
catalyt
motif
necessari
enzymat
function
among
gxxt
n
hr
motif
highli
conserv
set
residu
necessari
ntp
bind
hr
motif
form
coval
histidin
rna
within
crvi
motif
sequenc
similar
methyltransferas
mtase
domain
character
vsv
l
unknown
exactli
similar
cap
mechan
vsv
rsv
hmpv
detail
mechan
vsv
cap
biochemistri
provid
insight
cap
vsv
uniqu
accomplish
unconvent
rna
gdp
polyribonucleotidyltransferas
prntase
rather
vsv
cap
occur
two
part
start
convers
gtp
gdp
gtpase
follow
coval
attach
histidin
prna
form
phosphamid
bond
gdp
serv
nucleophil
attack
prna
result
releas
second
part
reaction
consist
mtase
reaction
use
sadenosylmethionin
methyl
nitrogen
cap
recent
crystal
structur
mtase
domain
hmpv
provid
addit
clue
reaction
see
figur
fragment
express
consist
criv
contain
put
mtase
addit
ctermin
kkg
motif
term
crvi
except
kkg
motif
fold
hmpv
mtase
domain
indic
conserv
fold
compar
crvi
activ
reaction
rate
slow
structur
biochem
result
clearli
identifi
activ
site
residu
suggest
mtase
requir
cofactor
addit
part
l
protein
catalyt
human
rhinoviru
hrv
enteroviru
polioviru
pv
nonenvelop
posit
strand
rna
virus
member
picornavirida
famili
picornavirus
replic
genom
use
rdrp
call
replic
take
place
one
two
form
primerdepend
format
de
novo
rna
de
novo
rna
synthesi
use
singl
initi
nucleotid
give
group
ad
sequenti
nucleotid
wherea
primerdepend
format
use
proteinbas
primer
oligonucleotid
hydroxyl
group
polymeras
picornaviru
famili
use
proteinprim
mechan
use
small
viral
peptid
vpg
initi
plu
minu
rna
synthesi
vivo
make
picornavirida
uniqu
initi
rna
synthesi
initi
use
highli
conserv
tyrosin
residu
within
vpg
use
cisact
replic
element
templat
whose
posit
vari
depend
aid
bind
two
ump
molecul
tyrosin
hydroxyl
group
product
reaction
vpgpu
extend
addit
uridin
form
locat
ctermin
end
longer
viral
polyprotein
approxim
kda
structur
solv
pv
among
mani
structur
polymeras
larg
similar
sequenc
domain
indic
polymeras
domain
adopt
righthand
configur
finger
palm
thumb
subdomain
provid
optim
arrang
substrat
metal
cation
access
catalyt
cycl
palm
finger
thumb
subdomain
contain
sequenc
motif
motif
palm
subdomain
shown
figur
motif
special
role
catalysi
includ
nucleotid
bind
overal
structur
integr
activ
palm
contain
activ
site
rdrp
structur
consist
antiparallel
betasheet
surround
three
alpha
addit
substructur
within
finger
domain
refer
index
middl
ring
pinki
pinki
finger
build
extend
betasheet
seem
conserv
index
finger
within
finger
subdomain
make
import
contact
thumb
subdomain
push
ring
finger
trap
conform
result
ring
finger
roof
ntp
entri
make
import
interact
triphosph
addit
structur
featur
motif
f
posit
charg
tunnel
modul
interact
tunnel
aid
diffus
nucleotid
conserv
among
famili
virus
protein
enzym
rare
exist
monomer
state
natur
energet
driven
higher
order
oligomer
state
polar
hydrophob
interact
disulfid
bond
format
develop
increasingli
sophist
structur
biolog
techniqu
includ
highresolut
xray
crystal
structur
cryoem
provid
snapshot
polymeras
may
adopt
oligomer
state
understand
character
oligomer
state
place
multifunct
enzym
greater
biolog
context
exampl
oligomer
state
impact
catalyt
function
polymeras
pv
pv
rdrp
describ
macromolecular
contact
two
polymeras
interfac
interfac
interfac
ii
interfac
defin
interact
thumb
domain
one
polymeras
palm
anoth
polymeras
interfac
ii
describ
interact
nterminu
one
polymeras
thumb
neighbor
polymeras
within
crystal
lattic
addit
pv
form
tubelik
structur
suggest
highli
dynam
structur
abl
undergo
adopt
multipl
conform
oligomer
state
pv
polymeras
requir
membraneassoci
rna
replic
infect
cell
demonstr
mutat
residu
involv
cov
part
larger
nidoviru
famili
except
larg
genom
kilobas
cov
posit
sens
rna
virus
notabl
exampl
sar
one
pathogen
member
viral
cov
genom
polyadenyl
gener
total
nonstructur
protein
twothird
genom
encod
nonstructur
protein
combin
form
replic
transcript
complex
complet
viral
rna
protein
rdrp
typic
compos
ntermin
domain
compos
nidovirusspecif
rdrpassoci
nucleotidyltransferas
niran
ctermin
contain
rdrp
domain
contain
set
six
conserv
motif
motif
af
respons
recogn
substrat
niran
domain
identifi
nidovirus
approxim
residu
long
sarscov
revers
genet
system
identifi
motif
requir
replic
viral
genom
niran
activ
directli
observ
outsid
revers
genet
system
cov
base
nucleotidyl
activ
eav
niran
domain
hypothes
play
role
protein
prime
cap
potenti
univers
ligat
activ
site
polymeras
locat
within
motif
c
compos
conserv
within
nidoviru
famili
seraspasp
residu
importantli
conserv
aspart
found
motif
sarscov
combin
found
motif
c
contribut
polymeras
rna
synthesi
activ
differ
posit
strand
rna
virus
contain
gdd
activ
site
motif
along
motif
c
aid
coordin
metal
ion
necessari
catalysi
sarscov
harbor
signatur
sequenc
motif
g
necessari
primerdepend
rna
due
difficulti
obtain
larg
enough
amount
highli
pure
protein
structur
cov
solv
either
xray
crystallographi
cryoem
therefor
structur
inform
current
avail
base
sole
structur
model
obtain
via
sequenc
align
homolog
model
techniqu
model
indic
righthand
fold
compos
finger
palm
thumb
subdomain
clearli
defin
entri
exit
channel
consist
rdrp
domain
structur
character
posit
sens
rna
polymeras
exampl
footandmouth
diseas
viru
clearli
distinct
known
molecular
topolog
negativestrand
rdrp
structur
model
predict
presenc
prime
loop
data
combin
biochem
data
indic
de
novo
initi
rna
synthesi
may
account
function
motif
g
complet
character
vitro
rdrp
activ
demonstr
overal
weak
activ
initi
evid
suggest
previous
uncharacter
ntermin
domain
may
requir
polymeras
howev
addit
domain
use
ctermin
tag
protein
still
yield
protein
poor
activ
process
base
result
increas
vitro
activ
two
nonstructur
protein
ad
protein
primer
extens
addit
appear
activ
increas
process
polymeras
allow
produc
rna
synthesi
product
nucleotid
presenc
link
subunit
togeth
also
increas
polymeras
reaction
effici
suggest
complex
format
may
influenc
reaction
rate
importantli
interact
complex
without
influenc
rna
synthesi
contain
exoribonucleas
domain
shown
decreas
nucleotid
mismatch
mani
way
similar
proofread
exoribonucleas
activ
correl
section
aim
answer
follow
question
import
medicin
chemist
biologist
drug
develop
work
field
virolog
clinic
relev
nucleosid
analog
potent
one
multipl
respiratori
virus
molecul
first
identifi
one
approv
commerci
use
molecul
like
ribavirin
analog
wide
use
treat
respiratori
viral
infect
current
approach
develop
new
nucleosid
analog
respiratori
rna
virus
broadspectrum
antivir
effect
ribavirin
guanosin
analog
first
report
found
time
ribavirin
inhibit
dna
rna
virus
includ
herpesvirus
vaccinia
vsv
well
respiratori
infect
caus
influenza
b
virus
parainfluenza
viru
ribavirin
current
approv
treatment
chronic
hcv
infect
combin
therapi
sever
rsv
infect
monotherapi
case
rsv
infect
ribavirin
administ
smallparticl
aerosol
requir
use
mask
tent
ribavirin
origin
develop
influenza
base
efficaci
mous
model
effect
human
clinic
trial
less
clear
approv
treatment
clinic
use
treatment
rsv
infect
via
aerosol
deliveri
remain
limit
due
inconveni
rout
administr
lack
clear
evid
efficaci
safeti
concern
associ
anemia
risk
teratogen
studi
evalu
mechan
action
ribavirin
produc
contradictori
result
usual
acknowledg
ribavirin
exert
main
effect
monophosph
metabolit
inhibit
host
inosin
monophosph
dehydrogenas
impdh
enzym
lead
deplet
intracellular
gtp
pool
result
indirect
inhibit
rna
synthesi
viral
replic
nucleosid
form
ribavirin
also
believ
enhanc
tcellmedi
immun
respons
increas
express
interferongamma
tumor
necrosi
addit
propos
prolong
replic
pv
presenc
ribavirin
increas
viral
mutat
frequenc
decreas
one
hypothesi
mutagen
effect
ribavirin
caus
triphosph
form
recogn
viral
rna
incorpor
viral
genom
ribavirin
monophosph
could
equal
base
pair
cytidin
uridin
therefor
caus
random
mutat
throughout
viral
genom
ribocytidin
adenosin
analog
contain
methyl
group
ribos
known
inhibitor
hcv
relat
member
flavivirida
one
potent
molecul
seri
develop
candid
treatment
hcv
infect
figur
adenosin
analog
also
inhibit
hrv
type
infect
vitro
valu
rang
subgenom
replicon
assay
use
transient
transfect
experi
demonstr
equipot
multipl
strain
hrv
type
c
import
proofofconcept
experi
demonstr
nucleosid
prevent
picornaviru
replic
like
inhibit
viral
rna
polymeras
function
class
effect
confirm
anoth
adenosin
analog
contain
figur
like
previous
known
inhibit
flavivirus
develop
candid
treatment
dengu
block
replic
dengu
viru
cell
cultur
mice
inhibit
rdrp
activ
therefor
possibl
would
inhibit
ssrna
virus
unexpect
inde
block
replic
anoth
enterovirusrel
vitro
antivir
effect
confirm
separ
studi
also
demonstr
vivo
investig
latter
studi
infect
immunocompromis
mice
intraperiton
inocul
treatment
infect
anim
given
oral
mgkg
twice
day
day
result
surviv
end
studi
compar
surviv
vehicl
control
group
develop
clinic
due
sever
toxic
seen
studi
rat
howev
result
summar
indic
nucleosid
analog
target
viral
rna
polymeras
rhinoviru
enterovirus
potenti
efficaci
preclin
anim
model
provid
rational
conduct
human
studi
safer
molecul
share
mode
action
fluorin
nucleosid
well
known
antivir
anticanc
properti
particular
guanosin
one
time
consid
potenti
candid
influenza
treatment
figur
vitro
inhibit
influenza
viru
replic
without
caus
appar
cell
ferret
treatment
mgkg
start
h
postinfect
significantli
reduc
influenza
viru
titer
nasal
wash
associ
reduct
fever
although
timeofaddit
experi
suggest
molecul
inhibit
earli
step
viru
replic
direct
evid
mechan
action
came
enzym
inhibit
cellfre
transcript
experi
triphosph
inhibit
influenza
viru
rna
polymeras
activ
compet
natur
gtp
inhibit
enzym
caus
incorpor
monophosph
viral
recent
relat
nucleosid
analog
cytidin
evalu
highli
pathogen
pandem
administ
intraperiton
significantli
enhanc
surviv
balbc
mice
infect
lethal
dose
either
virus
although
studi
show
compel
evid
vivo
efficaci
preclin
speci
suitabl
candid
clinic
develop
one
main
limit
molecul
lack
specif
influenza
viru
polymeras
abil
nucleotid
inhibit
distant
molecular
target
detriment
per
se
nucleotid
deriv
interact
rna
polymeras
substitut
fluoro
group
also
make
result
nucleotid
broad
substrat
dna
polymeras
latter
studi
author
shown
monophosph
form
incorpor
dna
human
dna
polymeras
alpha
gamma
might
explain
chang
cell
cycl
distribut
cytostat
effect
caus
prolong
vitro
incub
paradox
molecul
well
toler
administ
intraven
rat
woodchuck
one
hypothesi
discrep
low
organ
exposur
phosphoryl
metabolit
could
limit
toxic
effect
divid
cell
anim
antivir
favipiravir
avigan
approv
japan
treatment
influenza
infect
sinc
nucleosid
precursor
inhibit
influenza
viru
broadstrain
figur
often
propos
exert
antivir
activ
ntp
form
rtp
directli
inhibit
rdrp
activ
influenza
viru
exact
mode
action
precis
molecular
interact
nucleotid
viral
polymeras
elus
vitro
effici
convert
ribofuranosyl
rtp
form
cellular
treatment
influenza
virusinfect
cell
result
signific
increas
lethal
mutat
within
viral
genom
phenomenon
also
describ
error
lethal
mutagenesi
hypothesi
support
enzymat
assay
show
rtp
effici
recogn
influenza
viru
polymeras
guanosin
adenosin
addit
singl
event
rmp
incorpor
rna
influenza
viru
polymeras
delay
block
extens
rna
primer
strand
antivir
potenc
cover
viru
famili
well
beyond
orthomyxovirus
shown
inhibit
number
divers
rna
virus
unrel
influenza
includ
repres
norovirus
bunyavirus
arenavirus
flavivirus
interest
point
mutagen
effect
also
document
biochem
level
show
recogn
substrat
rna
synthesi
viral
polymeras
also
human
mitochondri
rna
hostbas
interact
result
measur
vitro
mitochondri
toxic
rais
question
mechan
action
compound
recent
possibl
exert
main
antivir
effect
without
convert
triphosph
form
came
observ
ribonucleosid
chemic
unstabl
biolog
even
though
seem
potent
inhibit
human
impdh
broad
antivir
spectrum
capac
induc
lethal
mutagenesi
somewhat
reminisc
ribavirin
anoth
nucleosid
inhibit
hcv
replic
hostbas
mechan
therefor
possibl
exert
inhibit
interact
host
protein
rule
remain
explor
consid
similar
ribavirin
term
antivir
spectrum
mode
action
interest
see
becom
wide
use
patient
suffer
respiratori
viral
infect
remain
limit
stockpil
potenti
influenza
pandem
japan
discoveri
parent
molecul
prodrug
lumicitabin
result
screen
campaign
use
focus
librari
structur
divers
nucleosid
nucleotid
analog
test
rsv
vitro
infecti
main
scaffold
identifi
screen
modif
posit
improv
antirsv
potenc
select
led
identif
figur
vitro
inhibit
broad
panel
rsv
b
subtyp
well
relat
pneumo
paramyxo
particular
recent
report
inhibit
rsv
hmpv
similar
vitro
molecular
target
determin
two
independ
method
polymer
function
rsv
l
protein
identifi
target
inhibit
first
select
character
drug
resistanceassoci
mutat
locat
l
gene
introduc
wildtyp
rsv
genom
four
amino
acid
mutat
phenotyp
associ
resist
enzymat
assay
use
purifi
recombin
rsv
polymeras
critic
valid
mode
action
assay
form
caus
immedi
chain
termin
rna
synthesi
inhibit
viral
polymer
activ
inhibitori
effect
specif
rsv
polymeras
sinc
inhibit
polymeras
host
virus
unrel
rsv
hcv
lack
inhibit
hcv
ration
molecular
model
predict
steric
clash
insid
activ
site
hcv
polymeras
low
oral
bioavail
seri
prodrug
evalu
improv
pharmacokinet
properti
one
prodrug
form
high
level
monophosph
triphosph
lung
administ
oral
nonhuman
primat
high
oral
bioavail
evalu
vivo
efficaci
african
green
monkey
infect
rsv
end
treatment
rsv
rna
undetect
bronchoalveolar
lavag
sampl
four
subsequ
random
doubleblind
clinic
trial
evalu
given
day
healthi
adult
inocul
reduct
viral
load
nasal
wash
associ
treatment
vari
depend
dose
regimen
rsv
rna
undetect
day
start
treatment
compar
day
placebo
assess
symptom
score
quantiti
mucu
produc
also
show
clear
effect
rsvinduc
diseas
import
result
repres
first
proofofconcept
valid
rsv
replic
inhibitor
efficaci
human
current
clinic
develop
treatment
rsv
infect
hospit
infant
adult
clinicaltrialsgov
identifi
recent
ebola
viru
outbreak
west
africa
trigger
increas
effort
identifi
new
antivir
target
filovirus
result
develop
new
seri
clink
nucleosid
analog
antiebola
properti
soon
cellbas
infecti
assay
clink
adenosin
deriv
compound
moder
activ
ebola
replic
valu
around
wherea
ethynyl
counterpart
complet
inact
also
broadspectrum
inhibitor
varieti
rna
virus
four
famili
filovirida
flavivirida
paramyxovirida
pneumovirida
includ
hcv
howev
addit
group
case
significantli
reduc
antivir
spectrum
hcv
rel
weak
antivir
activ
across
virus
attribut
ineffici
intracellular
phosphoryl
could
improv
ad
monophosph
prodrug
parent
nucleosid
result
compound
figur
inhibit
zair
sudan
speci
ebola
viru
marburg
viru
valu
rang
exhibit
moder
cytotox
multipl
human
cell
type
exhibit
broad
antivir
spectrum
parent
triphosph
form
recogn
substrat
rsv
polymeras
incorpor
rna
lead
immedi
chain
favor
vitro
data
led
evalu
macaqu
lethal
model
ebola
viru
diseas
complet
protect
achiev
administ
daili
intraven
dose
mgkg
begin
day
follow
phase
safeti
test
healthi
human
volunt
first
given
cours
compassion
use
ebolainfect
nurs
surviv
diseas
develop
recurr
central
nervou
soon
neonat
congenit
ebola
viru
infect
receiv
three
differ
experiment
therapi
includ
treatment
case
patient
clear
viru
surviv
infect
character
broad
antivir
spectrum
expand
anoth
ssrna
viru
famili
coronavirida
shown
inhibit
sarscov
merscov
replic
multipl
vitro
system
includ
primari
human
airway
epitheli
cell
cultur
submicromolar
also
effect
human
bat
cov
mous
model
sarscov
infect
prophylact
earli
therapeut
administr
reduc
lung
viral
load
improv
clinic
sign
diseas
well
respiratori
function
although
limit
data
confirm
propos
mechan
action
viru
gener
assum
molecul
target
rdrp
function
viral
polymeras
case
cov
support
identif
two
mutat
within
predict
finger
subdomain
rdrp
protein
murin
hepat
mutat
emerg
passag
confer
resist
combin
overal
reduc
replic
fit
point
precis
mechan
action
cov
remain
elus
possibl
triphosph
excis
proofread
activ
lack
immedi
chain
termin
observ
rsv
polymeras
case
could
resist
mutat
identifi
alter
chain
termin
profil
make
suscept
excis
studi
need
understand
work
also
design
new
molecul
cov
polymeras
review
summar
excit
advanc
discoveri
develop
novel
nucleosid
analog
potenti
new
treatment
respiratori
rna
viru
infect
medic
need
high
drug
approv
treatment
respiratori
viral
infect
despit
worldwid
health
impact
attribut
approv
drug
includ
zanamivir
oseltamivir
peramivir
favipiravir
japan
influenza
viru
palivizumab
rsv
limit
prevent
widespread
use
therapeut
set
drug
candid
intend
use
rhinoviru
infect
capsid
inhibitor
pleconaril
proteas
inhibitor
rupintrivir
test
clinic
without
success
first
nucleosid
analog
develop
respiratori
viral
infect
ribavirin
despit
approv
use
rsv
util
treat
sever
viral
infect
remain
low
therefor
concept
nucleosid
analog
respiratori
virus
remain
rel
new
need
explor
molecular
determin
polymeras
select
nucleotid
analog
current
understand
well
specif
chang
made
nucleotid
analog
alter
recognit
substrat
rna
synthesi
substrat
select
differ
among
posit
neg
strand
rna
viru
polymeras
exampl
mani
nucleotid
analog
known
inhibit
hcv
polymeras
often
antivir
spectrum
extend
flavivirus
picornavirus
howev
clear
mechanist
basi
explain
none
compound
inhibit
ssrna
virus
even
ssrna
virus
cov
could
exonucleaseproofread
activ
cov
polymeras
excis
chain
termin
resum
rna
synthesi
specif
amino
acid
within
activ
site
ssrna
viru
polymeras
respons
discrimin
nucleotid
hypothes
test
part
due
difficulti
conduct
biochem
structur
studi
viral
polymeras
respiratori
virus
recent
product
solubl
pure
viral
protein
target
limit
especi
case
larg
protein
complex
mention
earlier
review
develop
robust
express
system
influenza
polymeras
trimer
exampl
made
possibl
use
xray
crystallographi
potenti
cryoelectron
microscopi
provid
molecular
visual
bind
pocket
small
molecul
inhibitor
entri
exit
channel
substrat
potenti
new
way
disrupt
domain
interact
structur
insight
tremend
aid
develop
new
drug
well
elucid
mechan
action
bind
exist
drug
protein
target
molecular
model
also
use
approach
other
use
ration
differ
select
lumicitabin
rsv
hcv
studi
one
need
ration
design
new
nucleotid
analog
target
respiratori
viru
polymeras
past
mani
nucleosid
analog
fail
develop
safetytox
reason
especi
molecul
suboptim
specif
viral
polymeras
target
use
chronic
treatment
infect
hiv
hcv
context
acut
respiratori
infect
evalu
safeti
must
base
intend
durat
treatment
target
patient
sometim
includ
vulner
popul
children
elderli
consider
ensur
success
futur
develop
nucleosid
analog
direct
respiratori
infect
optim
deliveri
lung
evalu
differ
rout
administr
includ
aerosol
formul
develop
lungtarget
nucleosid
prodrug
despit
challeng
prospect
develop
nucleosid
analog
direct
respiratori
rna
viru
infect
repres
excit
new
avenu
antivir
research
